Aclaris Therapeutics vs Adagene
Aclaris Therapeutics and Adagene are similar in size: $7.8m and $7.7m of revenue in their latest fiscal years. Adagene grew faster (7332.8% against -58.2%). Adagene kept more of each dollar of sales as profit: a net margin of -229.6% against -829.6%. Aclaris Therapeutics carries less debt relative to equity (0.0% against 17.3%).
| Latest fiscal year | Aclaris TherapeuticsACRS, 2025 | AdageneADAG, 2025 |
|---|---|---|
| Revenue | $7.8m | $7.7m |
| Revenue growth | -58.2% | 7332.8% |
| Net income | −$64.9m | −$17.6m |
| Operating margin | -975.9% | -279.5% |
| Net margin | -829.6% | -229.6% |
| Return on equity | -50.2% | -41.0% |
| Free cash flow | −$47.2m | −$15.7m |
| Cash | $20.0m | $74.5m |
| Total debt | $0 | $6.1m |
| Debt to equity | 0.0% | 17.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 73 | — |
| Market value | $515m | $113m |
| Price vs our value range | — | — |
| Moat score | 14 (Weak) | — |
| Insider trades, 12 months | 0 buys, 1 sales | 5 buys, 0 sales |